• Sunovion Pharmaceuticals Inc., of Marlborough, Mass., reported results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to Latuda (lurasidone HCl). Read More
• Janssen Research & Development LLC, of Raritan, N.J., a subsidiary of Johnson & Johnson, submitted a supplemental new drug application to the FDA for the use of Xarelto (rivaroxaban), an oral anticoagulant, to reduce the risk of stent thrombosis in patients with acute coronary syndrome. Read More
• ImmunoCellular Therapeutics Ltd., of Woodland Hills, Calif., said that its double-blind, placebo-controlled Phase II trial of ICT-107, a vaccine for glioblastoma multiforme, has been initiated at 25 sites, and has enrolled 189 patients. About 200 subjects will be enrolled to treat 102 patients with HLA-A1/A2 immunological subtypes. Read More
• China Nuokang Bio-Pharmaceutical Inc., of Beijing, received a proposal from its chairman and CEO, Baizhong Xue, to take the company private by acquiring all outstanding shares for $5.80 per American Depositary Share. Each Nuokang ADS represents eight Nuokang ordinary shares. Read More
Though FDA reviewers highlighted concerns of renal impairment in briefing documents disclosed ahead of Friday's advisory panel meeting on Gilead Sciences Inc.'s HIV drug Quad, analysts continue to expect a thumbs-up for the single-tablet regimen, comprising the active ingredients of Truvada (emtricitabine/tenofovir disoproxil fumarate) plus elvitegravir and boosting agent cobicistat. Read More
Six months after raising $69 million to support the anticipated launch of hepatitis B vaccine Heplisav, Dynavax Technologies Corp. is at it again. The Berkeley, Calif.-based biotech completed another public offering, this time raising $74.4 million for more Heplisav ramp-up. Read More
GlaxoSmithKline plc's $2.6 billion acquisition offer for Rockville, Md.-based Human Genome Sciences Inc. (HGS) turned hostile when GSK announced that it would not participate in a strategic alternatives review process with HGS, and that it would instead commence its tender offer for all outstanding shares for $13 per share in cash, which it first put forward April 11. Read More
